HER-2/neu gene product in serum - An oncoprotein in the diagnosis and therapy of breast carcinoma

被引:0
|
作者
Schulze, G [1 ]
机构
[1] HELIOS Klinikum Berlin, Inst Lab Diagnost, D-13125 Berlin, Germany
关键词
breast cancer; Herceptin; HER-2; erb-B2; oncoprotein;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The HER-2/neu oncogene codes a protein of the family of epidermal growth factor receptors. The extracellular domain has a MW from 95-105 kDa and is shed into the blood. In some patients with malignant tumors there is a high expression of HER-2/neu connected with high levels of HER-2/neu protein in the serum. High concentrations signal aggressive growth, bad prognosis and shorter survival. The reference range lies between 4.0 and 14.0 ng/ml with a mean of 9.0 ng/ml There is a significant difference of values between patients with and without metastases, but not between healthy people and patients without metastases. The advantage of this parameter lies in the early diagnosis of recurrence in the therapy of metastasizing breast carcinomas especially on treatment with Herceptin.
引用
收藏
页码:1007 / 1010
页数:4
相关论文
共 50 条
  • [21] Serum HER-2/neu levels in clinical studies with lapatinib in HER-2/neu positive breast cancer
    Maltzman, J.
    Blackwell, K.
    Stein, S.
    Martin, A.
    Westland, R.
    Burstein, H.
    Gomez, H.
    Gartner, N.
    Platek, G.
    Newmiller, M.
    Lipton, A.
    Carney, W. P.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A130 - A130
  • [22] Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma
    Bermont, L
    Algros, MP
    Baron, MH
    Adessi, GL
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 63 (02) : 163 - 169
  • [23] Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma
    Laurent Bermont
    Marie-Paule Algros
    Marie-Hélène Baron
    Gérard L. Adessi
    Breast Cancer Research and Treatment, 2000, 63 : 163 - 169
  • [24] RADIOLABELED ANTIBODY TARGETING OF THE HER-2/NEU ONCOPROTEIN
    DESANTES, K
    SLAMON, D
    ANDERSON, SK
    SHEPARD, M
    FENDLY, B
    MANEVAL, D
    PRESS, O
    CANCER RESEARCH, 1992, 52 (07) : 1916 - 1923
  • [25] Radioiodinated antibody targeting of the HER-2/neu oncoprotein
    Xu, FJ
    Yu, YH
    Bae, DS
    Zhao, XG
    Slade, SK
    Boyer, CM
    Bast, RC
    Zalutsky, MR
    NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (05): : 451 - 459
  • [26] Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
    Lipton, A
    Leitzel, K
    Ali, SM
    Demers, L
    Harvey, HA
    Chaudri-Ross, HA
    Evans, D
    Lang, R
    Hackl, W
    Hamer, P
    Carney, W
    CANCER, 2005, 104 (02) : 257 - 263
  • [27] Elevated serum HER-2/neu Oncoprotein levels predict decreased response to hormone therapy in women with metastatic breast cancer.
    Carney, WP
    Ali, SM
    Brady, C
    Chinchilli, V
    Demers, LM
    Hamer, PJ
    Leitzel, K
    Nalin, C
    Lipton, A
    CLINICAL CHEMISTRY, 2002, 48 (06) : A16 - A16
  • [28] Serum HER-2/neu in the management of breast cancer patients
    Lüftner, D
    Lüke, C
    Possinger, K
    CLINICAL BIOCHEMISTRY, 2003, 36 (04) : 233 - 240
  • [29] Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
    Lal, P
    Salazar, PA
    Ladanyi, M
    Chen, BY
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (03): : 155 - 159
  • [30] Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients
    Sahin, Feride Iffet
    Yilmaz, Zerrin
    Yagmurdur, Mahmut Can
    Atac, Fatma Belgin
    Ozdemir, Binnaz Handan
    Karakayali, Hamdi
    Demirhan, Beyhan
    Haberal, Mehmet
    PATHOLOGY & ONCOLOGY RESEARCH, 2006, 12 (04) : 211 - 215